Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Multicenter Phase II Study Evaluating Two Dosing Schedules of TG4010(MVA-MUC1-IL2) in Patients With Adenocarcinoma of the Prostate

NCT00040170 is registered in ClinicalTrials.gov with Transgene as lead sponsor.

NCT NCT00040170
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00040170 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Multicenter Phase II Study Evaluating Two Dosing Schedules of TG4010(MVA-MUC1-IL2) in Patients With Adenocarcinoma of the Prostate
Lead sponsor
Transgene
Phase
Phase 2
Overall status
Terminated
Start date
May 31, 2002
Completion date
Not reported
Enrollment
50
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

prostatic neoplasms